

Anti-PEG10 Antibody (1E2-F12-C12)

Mouse Monoclonal Antibody Catalog # ABV12052

Product Information

Application WB, IP **Primary Accession Q86TG7** Reactivity Human Host Mouse Clonality Monoclonal Isotype Mouse IgG1 **Clone Names** 1E2-F12-C12 **Calculated MW** 80173

Additional Information

Gene ID 23089

Application & Usage

Other Names

WB; HeLa cell lysate, IP: HeLa cell lysate

Retrotransposon-derived protein PEG10, Embryonal carcinoma

differentiation-regulated protein, Mammalian retrotransposon-derived protein 2, Myelin expression factor 3-like protein 1, MEF3-like protein 1

Target/Specificity PEG10

Antibody Form Liquid

Appearance Colorless liquid

Formulation In buffer containing 0.1M Tris-Glycine (pH 7.4, 150 mM NaCl) with 0.2%

sodium azide, 50%, glycerol

Handling The antibody solution should be gently mixed before use.

Reconstitution & Storage -20 °C

Background Descriptions

Precautions

Anti-PEG10 Antibody (1E2-F12-C12) is for research use only and not for use in

diagnostic or therapeutic procedures.

Protein Information

Name PEG10 {ECO:0000303 | PubMed:11318613,

ECO:0000312 | HGNC:HGNC:14005}

Function Retrotransposon-derived protein that binds its own mRNA and

self-assembles into virion-like capsids (PubMed:34413232). Forms virion-like extracellular vesicles that encapsulate their own mRNA and are released from cells, enabling intercellular transfer of PEG10 mRNA (PubMed:34413232). Binds its own mRNA in the 5'-UTR region, in the region near the boundary between the nucleocapsid (NC) and protease (PRO) coding sequences and in the beginning of the 3'-UTR region (PubMed:34413232). Involved in placenta formation: required for trophoblast stem cells differentiation (By similarity). Involved at the immediate early stage of adipocyte differentiation (By similarity). Overexpressed in many cancers and enhances tumor progression: promotes cell proliferation by driving cell cycle progression from G0/G1 (PubMed:12810624, PubMed:16423995, PubMed:26235627, PubMed: 28193232). Enhances cancer progression by inhibiting the TGF-beta signaling, possibly via interaction with the TGF-beta receptor ACVRL1 (PubMed: 15611116, PubMed: 26235627, PubMed: 30094509). May bind to the 5'-GCCTGTCTTT-3' DNA sequence of the MB1 domain in the myelin basic protein (MBP) promoter; additional evidences are however required to confirm this result (By similarity).

Cellular Location

Extracellular vesicle membrane. Cytoplasm. Nucleus Note=Forms virion-like extracellular vesicles that are released from cells (PubMed:34413232). Detected predominantly in the cytoplasm of breast and prostate carcinomas, in hepatocellular carcinoma (HCC) and B-cell chronic lymphocytic leukemia (B-CLL) cells and in the Hep-G2 cell line (PubMed:12810624).


Tissue Location

Expressed in the cytotrophoblast layer but not in the overlying syncytiotrophoblast of the placenta. Expressed in prostate and breast carcinomas but not in normal breast and prostate epithelial cells. Expressed in the Hep-G2 cell line (at protein level) Expressed in brain, liver, spleen, kidney, thymus, lung, ovary, testis, reactive lymph node, skeletal muscle, adipose tissue and placenta Expressed in pancreatic and hepatocellular carcinomas (HCC)

Background

Prevents apoptosis in hepatocellular carcinoma (HCC) cells through interaction with SIAH1, a mediator of apoptosis. May also have a role in cell growth promotion and hepatoma formation. Inhibits the TGF-beta signaling by interacting with the TGF-beta receptor ALK1. When overexpressed, induces the formation of cellular extension, such as filipodia in association with ALK1. Involved at the immediate early stage of adipocyte differentiation (By similarity). May bind to the 5'-GCCTGTCTTT-3' DNA sequence of the MB1 domain in the myelin basic protein (MBP) promoter.


Images



Western blot detection of PEG10 in HeLa cell lysates using PEG10 mouse mAb

Immunoprecipitation analysis of Hela cell lysates using

PEG10 mouse mAb.



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.